Skip to main content

MoneyWorks4Me

Lupin informs about press release

06 Dec 2023 Evaluate

Lupin has informed that it enclosed a Press Release as regards, receipt of U.S. FDA approval for the Company’s Abbreviated New Drug Application for Varenicline Tablets, 0.5 mg and 1 mg, to market a generic equivalent of Chantix® Tablets, 0.5 mg and 1 mg, of PF Prism C.V. 

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1903.00
Dr. Reddys Labs. 1398.00
Cipla 1416.00
Lupin 1999.00
Zydus Lifesciences 1200.00
View more..